Sue Hendrickson is co-head of the firm's Technology Transactions and Life Sciences Transactions practices. She has 25 years of experience representing leading companies in connection with cutting-edge intellectual property issues and the development and commercialization of new products and technologies. Her practice focuses on technology transactions, including complex collaborations, licensing deals, strategic investments, development, manufacturing and distribution agreements, acquisitions, and joint ventures. She has extensive experience in the information technology, life sciences, healthcare, communications, media, consumer products, and financial sectors, and regularly represents clients ranging from startups to Fortune 100 companies, as well as investors, and nonprofits. Ms. Hendrickson also regularly advises on confidentiality, trade secret, social media issues, and intellectual property matters.
- Samsung in connection with the launch of Samsung's voice-activated personal assistant.
- Digital Entertainment Content Ecosystem, a consortium of leading electronics, media, and other companies involved in digital entertainment, in connection with the development and rollout of the UltraViolet service, a cloud-based digital rights authentication system that allows consumers to stream and download content to multiple platforms and devices.
- LeanIn.org in connection with its partnership with Getty Images to create the Lean In Collection, a library of images devoted to celebrating powerful images of women, girls, and the communities who support them; the Ban Bossy Campaign, its partnership with the Girl Scouts, and other ongoing activities relating to the advancement of women and LeanIn.org's mission.
- Barnes & Noble in connection with commercial partnering transactions and intellectual property and compliance issues relating to the global rollout of the NOOK®.
- AOL for two decades in connection with strategic alliances, joint ventures, content and technology licenses, product development agreements, advertising agreements, marketing deals, and the IP and commercial aspects of more than 20 acquisitions of strategic intellectual property rights and technology platforms.
- Geisinger Health System in connection with the establishment of xG Health Solutions and the licensing of intellectual property rights in Geisinger's market-leading health care performance intellectual property technologies to xG.
- xG Health Solutions in connection with IP, licensing, and commercial matters, including collaborations involving the development of healthcare related apps.
- Medicis Pharmaceutical Corporation in connection with research, development, licensing, manufacturing, and other commercial matters, including in strategic investment in Revance Therapeutics, Inc. and the purchase of an option to acquire Revance or to license exclusively in North America Revance's novel topical botulinum toxin type A product under clinical development.
- Multiple pharmaceutical, biotech, and medical device companies in connection with licensing, product development, manufacturing, clinical trial and marketing agreements.
- Various private equity groups and other investors in connection with technology-oriented investments and commercial and IP matters involving portfolio companies.
"Washington, DC Lawyer of the Year" – Technology Law (2013, 2017, 2019)
- JD, Harvard Law School, 1993
- MPP, Harvard University, John F. Kennedy School of Government, 1993
- BA, Harvard College, 1987, magna cum laude
- District of Columbia
- New York
Member, Licensing Executives Society
Founding Member and Board Member, Women in Bio